Craig-Hallum Initiates Coverage On LifeMD with Buy Rating, Announces Price Target of $10
Portfolio Pulse from Benzinga Newsdesk
Craig-Hallum analyst Alex Fuhrman has initiated coverage on LifeMD (NASDAQ: LFMD) with a Buy rating and set a price target of $10.
November 30, 2023 | 5:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
LifeMD receives a Buy rating from Craig-Hallum with a price target of $10, indicating a positive outlook from the analyst.
The initiation of coverage by Craig-Hallum with a Buy rating and a price target that is potentially higher than the current trading price suggests a positive sentiment towards LifeMD's stock. This could lead to increased investor interest and a potential short-term rise in the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100